Critical role for macrophage migration inhibitory factor (MIF) in Ross River virus-induced arthritis and myositis

Lara J. Herrera-a,b, Michelle Nelson-a, Anon Srikiatkhamchorn-a, Ran Gu-d, Surapee Anantapreechae-a, Günter Fingerle-Rowson-f, Richard Bucalag-a, Eric Morand-d, Leilani L. Santos-a,b,1, and Suresh Mahalingam-a,b,1,2

*Virus and Inflammation Research Group, Faculty of Applied Science, University of Canberra, Canberra, ACT 2601, Australia; bEmerging Viruses and Inflammation Research Group, Institute for Glycomics, Griffith University, Gold Coast, QLD 4215, Australia; cDepartment of Medicine, University of Massachusetts Medical School, Worcester, MA 01655; dCentre for Inflammatory Diseases, Southern Clinical School, Monash University, Melbourne, VIC 3168, Australia; eNational Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand; fDepartment of Hematology and Oncology, University Hospital Cologne, D-50924 Cologne, Germany; and gDepartment of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511

Edited by Diane E. Griffin, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, and approved June 10, 2011 (received for review February 20, 2011)

Arthrogenic alphaviruses, such as Ross River virus (RRV), chikungunya, Sindbis, mayaro and o’nyong-nyong viruses circulate endemically worldwide, frequently causing outbreaks of polyarthritis. The exact mechanisms of how alphaviruses induce polyarthritis remain ill defined, although macrophages are known to play a key role. Macrophage migration inhibitory factor (MIF) is an important cytokine involved in rheumatoid arthritis pathogenesis. Here, we characterize the role of MIF in alphavirus–induced arthritides using a mouse model of RRV-induced arthritis, which has many characteristics of RRV disease in humans. RRV-infected WT mice developed severe disease associated with up-regulated MIF expression in serum and tissues, which corresponded to severe inflammation and tissue damage. MIF-deficient (MIF−/−) mice developed mild disease accompanied by a reduction in inflammatory infiltrates and muscle destruction in the tissues, despite having viral titers similar to WT mice. In addition, reconstitution of MIF into MIF−/− mice exacerbated RRV disease and treatment of mice with MIF antagonist ameliorated disease in WT mice. Collectively, these findings suggest that MIF plays a critical role in determining the clinical severity of alphavirus–induced musculoskeletal disease and may provide a target for the development of antiviral pharmaceuticals. The prospect being that early treatment with MIF-blocking pharmaceuticals may curtail the debilitating arthritis associated with alphaviral infections.

methotrexate | proinflammatory cytokine | migration inhibitory factor antagonist | immunology | viral arthritis

Mosquito-borne alphaviruses are an important cause of both encephalitic and arthritic disease in humans. Alphaviruses within the Togaviridae family, including Ross River virus (RRV) and chikungunya virus (CHIKV), are a major cause of debilitating arthritic disease worldwide (1). Of particular concern is the ability of this group of viruses to cause extensive epidemics of polyarthritis and arthralgia, often associated with chronic symptoms and ongoing health issues, making infection with these viruses an illness of major socioeconomic significance (1–3). Examples of such large-scale outbreaks of alphavirus include the 1979 to 1980 outbreak of RRV in the South Pacific, which resulted in more than 60,000 reported cases (4), and the recent reemergence of CHIKV in the French island of La Réunion, which saw more than 250,000 people infected (5). From La Réunion, CHIKV rapidly spread to the Indian Ocean, India, and South East Asia, with estimates as high as 5 million reported cases since 2006 (6–8). Currently, CHIKV continues to circulate in the Asia Pacific region, causing sporadic outbreaks, the most recent being the 2009 outbreaks in South East Asia affecting more than 100,000 people (9–11); furthermore, infection with CHIKV among travelers has been reported in Europe and the United States (12).

RRV is a positive-sense RNA virus that circulates endemically in Australia and the South Pacific (4) and is maintained in transmission cycles between its mosquito vector and vertebrate hosts (13). In Australia, roughly 5,000 cases of RRV are reported annually (4), with symptoms of arthritis, arthralgia, myalgia, fatigue, febrile illness, and rash (4, 14, 15). Acute symptoms can last for weeks to months; however, chronic arthritic disease associated with RRV infection has been reported to last up to a year or more (16). Currently, the only treatment available for patients suffering arthrogenic alphavirus infections is symptomatic care in the form of nonsteroidal anti-inflammatory drugs (4, 16).

Research into the pathogenesis of arthritis related to alphavirus infection has been aided by the development of a mouse model of RRV-induced disease (17). Aspects of the disease progression in the mouse model resemble that seen in human disease (18–20). Using this model, we have previously identified a number of host immune factors that contribute to the development of RRV-induced disease, including the critical role that macrophages play in the pathogenesis of RRV disease (19–21).

Alphaviral disease has many similarities to rheumatoid arthritis (RA), including the critical involvement of macrophages and inflammatory molecules. Macrophage migration inhibitory factor (MIF), a proinflammatory cytokine secreted by a variety of cell types, is a potent monocyte/macrophage chemotactant and activator (22). MIF has an established role in RA (23, 24), being elevated in synovial fluid, tissues, and serum of patients with RA (25, 26). Inhibition of its function by antibody blockade, or through genetic deletion, significantly reduces the inflammation and destruction associated with mouse models of RA (27, 28). The role of MIF in viral-induced inflammatory diseases is unknown. MIF has been shown to be up-regulated in patients presenting with both Dengue virus infection (29) and West Nile virus (WNV) infection (30). Such studies show an association between MIF and viral disease, but are limited in determining its role in disease pathogenesis, leaving the involvement of MIF in viral infection largely uncharacterized.

In the present study, we investigated the role of MIF in the pathogenesis of alphaviral arthritic disease, using the mouse model of RRV-induced disease. We found that in the absence of MIF, RRV infection resulted in reduced clinical disease severity, corresponding to a decrease in tissue inflammation and damage. These decreases were associated with reductions in cellular infiltrates, monocyte chemotactic protein-1 (MCP-1), and IFN-γ, despite the presence of intact viral immunity. These investigations show that MIF plays a pivotal role in alphavirus-induced arthritis by regulating proinflammatory molecule expressions in the tissue


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

1L.L.S. and S.M. contributed equally to this work.

2To whom correspondence should be addressed. E-mail: s.mahalingam@griffith.edu.au.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1101089108/-/DCSupplemental.
Microenvironment and not by affecting viral immunity. These investigations also highlight the therapeutic potential of MIF antagonist in the treatment of alphavirus arthropathies.

Results
MIF Is Up-Regulated Following RRV Infection. To determine if MIF was up-regulated in response to RRV infection, 20-d-old C57BL/6 WT mice were infected with 10^7 pfu RRV or mock-infected with diluent alone. At time points before disease onset [day 1 postinfection (p.i.)] and at the time of disease onset (day 5 p.i.), mice were killed, serum collected, and MIF levels determined by ELISA. At disease onset, MIF serum levels in RRV-infected mice showed a significant (P < 0.05) increase compared with mock-infected controls (Fig. 1). To determine if MIF was expressed at the sites of inflammation, immunohistochemistry (IHC) was performed on quadriiceps muscle and ankle joint sections of RRV-infected mice at disease onset (day 5 p.i.) and at peak disease (day 10 p.i.). Some MIF expression was present in the ankle joints of mock-infected mice (Fig. 2 A ii and D ii); however, expression was markedly increased in the ankle joints of RRV-infected mice both at disease onset (Fig. 2B iv) and at peak disease (Fig. 2 D iv). MIF was not detected in the quadriiceps muscle of mock-infected mice (Fig. 2 A ii and C ii) or during disease onset (Fig. 2 A iv). In contrast, MIF was prominently detected in the quadriiceps of RRV-infected mice at peak disease (Fig. 2C iv). Overall, comparison of MIF immunostaining between mock-infected and RRV-infected mice demonstrated greater staining for MIF positive cells in RRV-infected mice.

RRV-Induced Inflammatory Disease Is Less Severe in MIF Knockout Mice. To assess the role of MIF in RRV disease, C57BL/6 WT mice and C57BL/6 mice deficient in MIF were infected with 10^7 pfu RRV and monitored for disease signs (Fig. 3A). As expected, WT mice developed severe disease signs associated with severe hindlimb weakness, loss of gripping ability (Fig. 3A), and weight loss during stages of peak disease (Fig. 3B). In contrast MIF−/− mice developed only mild disease signs with significantly (P < 0.05) lower peak disease scores (Fig. 3A) and no signs of weight loss (Fig. 3B). Although RRV-infection had a significantly diminished impact on weight gain in MIF−/− mice (compared with mock-infected controls), actual weight loss was not observed at any point during the course of RRV disease (Fig. 3B), whereas RRV-infected WT mice lost weight at the onset of peak disease. Mock-infected mice were scored zero on the clinical scale, indicating no signs of disease for the duration of the experiment.

MIF Deficiency Does Not Compromise Antiviral Immunity. To determine if the differences in disease severity reflected a reduction in RRV replication, C57BL/6 WT and MIF−/− mice were infected with 10^7 pfu RRV and killed at days 1, 3, 5, and 10 p.i. Serum, ankle joints, and quadriiceps muscles were isolated and assayed for viral titers by plaque assay. Serum titers were comparable at all days tested, indicative of equivalent systemic replication. Serum titers fell below the limit of detection by day 5 (Fig. S1A). At day 1 p.i., RRV titers recovered from quadriiceps muscles and ankle joints of WT and MIF−/− mice were comparable (Fig. S1B), as were the titers at days 3, 5, and 10 p.i. from quadriiceps muscles. In contrast, despite the initial infection reaching the same titers in ankle tissues, viral titers at later stages of infection were slightly lower in MIF−/− mice compared with WT mice (Fig. S1C), suggesting that MIF deficiency does not adversely affect the host response to viral infection.

MIF Deficiency Reduces RRV-Induced Inflammation and Tissue Destruction. We have previously shown that peak disease in RRV-infected WT C57BL/6 mice corresponds to severe inflammation of the quadriiceps muscle and ankle joints (20). To determine if the reduction in disease severity in MIF−/− mice corresponded to a reduction in inflammation, quadriiceps muscles and ankle joint tissues of WT and MIF−/− RRV-infected mice were collected at peak disease (day 10 p.i.) for histological analysis. No inflammation was observed in the quadriiceps muscle (Fig. 4 A i and ii) and ankle joint (Fig. 4 B i and ii) of the tissue infected with mock-infected WT mice. RRV-infected WT mice showed a significant (P < 0.05) increase compared with mock-infected MIF−/− mice, given that RRV infection in both quadriiceps muscle (Fig. 4 A iii) and ankle joint (Fig. 4 B iii), with large numbers of inflammatory infiltrates and extensive disruption of striated muscle fibers. In contrast, RRV-infected MIF−/− mice showed reduced inflammation in quadriiceps muscle (Fig. 4 A iv) and ankle joint (Fig. 4 B iv), with fewer infiltrating cells compared with tissues from WT mice and no apparent disruption of striated muscle fibers.

To further investigate whether RRV infection of MIF−/− mice show reduced tissue destruction compared with WT mice, damage to quadriiceps muscle was assessed by myofiber permeability to Evan’s blue dye (EBD). At day 10 p.i., corresponding to peak inflammatory disease, RRV-infected WT and MIF−/− mice were injected intraperitoneally with 1% EBD before being killed. Quadriiceps muscles were collected, snap-frozen in OCT compound, cryosectioned, and EBD+ cells identified by fluorescence microscopy. Mock-infected WT and MIF−/− mice showed only background staining, with no EBD+ cells evident (Fig. S2 A and B). The quadriiceps muscle of RRV-infected WT mice displayed abundant EBD+ cells (Fig. S2 C), indicative of extensive muscle tissue damage, whereas MIF−/− mice showed substantially less EBD+ cells (Fig. S2 D). Taken together, these results demonstrate a role for MIF in the development of inflammation and tissue damage that contribute to the pathogenesis of RRV-induced disease.

MIF Modulates Proinflammatory Cytokines in RRV-Induced Disease. It is well established that cytokines play crucial roles in inflammatory disease processes. Given that RRV-infected MIF−/− mice develop mild disease compared with infected WT mice, it was important to determine the expression and production of proinflammatory factors in the absence and presence of MIF. At peak disease (day 10 p.i.), quadriiceps muscle and ankle joint tissues were isolated and cytokine levels measured by real-time PCR. MCP-1 and IFN-γ mRNA expression were significantly lower in both quadriiceps muscles and ankle joints of MIF−/− mice compared with WT mice (Fig. S3 A). However, TNF-α was not affected by MIF deficiency, with no significant difference in expression between MIF−/− and WT mice in both tissues (Fig. S3 A).

To assess whether the mRNA expression changes are observed at the protein level, quadriiceps muscle and ankle joint tissues were isolated from infected WT and MIF−/− mice at peak disease (day 10 p.i.) and tissues homogenized for cytokine measurement by ELISA. The effects of MIF deficiency on cytokine production largely complemented mRNA-expression analysis, with MIF−/− mice exhibiting significantly lower MCP-1 and IFN-γ protein levels in ankle joint tissue, significantly lower MCP-1 protein levels in quadriiceps muscle, and no significant difference in tissue TNF-α protein levels (Fig. S3 B). We also assessed the affect of MIF deficiency on tissue MCP-1, IFN-γ, and TNF-α protein levels.
during the early stages of RRV infection (days 1, 3, and 5 p.i.) (Fig. S4). MCP-1 protein levels were consistently and significantly lower in both quadriceps muscle and ankle joints of MIF−/− mice compared with WT mice, but no significant differences in the levels of TNF-α were seen. IFN-γ protein levels were significantly lower at day 3 p.i. in MIF−/− mice compared with WT mice but levels were not significantly different at day 5 p.i. Interestingly, IFN-γ protein levels were increased in MIF−/− mice at day 1.

Reintroduction of Recombinant MIF into Mice Exacerbates Disease. To further confirm the role of MIF in the development of severe RRV-induced inflammatory disease, we assessed the effects of reintroducing recombinant murine MIF (rMIF) into RRV-infected MIF−/− mice on disease signs and changes in body weight. RRV-infected MIF−/− mice were either administered with 50 ng rMIF or given vehicle control. Uninfected MIF−/− mice, both untreated and treated with rMIF, were included as additional controls. As expected RRV-infected MIF−/− mice without MIF treatment developed mild disease; however, RRV-infected MIF−/− mice treated with rMIF developed severe disease signs, with mice exhibiting moderate to severe hindlimb weakness and dragging (Fig. S5A). In addition, RRV-infected MIF−/− mice treated with rMIF showed significantly less weight gain (Fig. S5A).

Experiments were repeated in RRV-infected WT mice to determine whether the administration of rMIF can increase disease severity in WT mice. Consistent with earlier observations, WT mice infected with RRV developed severe disease. Strikingly, RRV-infected WT mice treated with rMIF developed more pronounced disease with mice showing complete loss of hindlimb function (Fig. S5B). Interestingly, the addition of rMIF in WT mice appeared to prolong disease signs, with mice showing severe disease signs past day 18, the point at which the disease had resolved in mice that were RRV-infected alone. Treatment of mice with rMIF also affected body weight, with weights decreasing at day 7 and remaining low for the duration of the experiment. (Fig. S5B).

Treatment with ISO-1 MIF Antagonist Ameliorates RRV Arthritic Disease. To determine the potential of MIF to act as a pharmaceutical target to treat alphaviral disease, WT C57BL/6 mice were infected with RRV as previously shown. At the onset of clinical signs, mice were treated with 50 μL of either the MIF ISO-1 antagonist (equivalent to 50 μg) or diluent via the intraperitoneal route, with treatments continuing every 24 h up to day 14 p.i. Treated mice developed only mild disease compared with the mock-treated control mice, with a significant decrease in arthritic disease from days 11 to 15 p.i. (Fig. 6). MIF antagonist-treated mice failed to develop the hindlimb dysfunction seen in the mock-treated mice and MIF antagonist treatment resulted in less disease induced weight reduction (Fig. S6).

Discussion
The impact that alphaviral disease has on quality of life, combined with the fact that alphaviruses circulate worldwide—frequently causing large epidemics—makes this group of viruses a global concern and highlights the importance of research into
potential anti–alphaviral therapies. Ongoing research into the pathogenesis of alphaviral disease has revealed numerous similarities between alphaviral-induced arthritic disease and RA including an important role of macrophages and the contribution of proinflammatory cytokines and chemokines (16–18, 21).

MIF has long been recognized as an important proinflammatory cytokine in RA. Given the similarities between alphaviral-induced arthritis and RA, we hypothesized a similarly critical role for MIF in RRV-induced arthritic disease. In this study we have used the mouse model of RRV disease to show that MIF plays a pivotal role in the development of inflammatory arthritis in alphaviral-induced disease. Mice deficient in MIF, either through gene knockout or treatment with a MIF antagonist, were significantly protected from the severe arthritic disease observed in RRV-infected WT mice, corresponding to a significant reduction in inflammation in the joint and the muscle tissues of RRV-infected mice. MIF deficiency reduced MCP-1 mRNA and protein expression following RRV infection, and decreased macrophage infiltration into muscle and joint tissues, resulting in reduced tissue damage and significant amelioration of disease signs. Furthermore, the reintroduction of MIF into mice with rMIF reestablished the susceptibility of these mice to severe RRV-induced arthritic disease. The amelioration of signs in this model provides compelling evidence that MIF is a viable target for therapy, and that MIF antagonists, such as the MIF ISO-1 antagonist, may find application in the treatment of alphaviral arthritides in humans.

MIF is a cytokine with critical functions in both the innate and adaptive immune systems (23, 24, 31). Of particular interest is the role MIF plays in the innate immune system, where it has been identified as a key regulator (32). The innate immune system has been shown to play an important role in the pathogenesis of RA (33), with the role of MIF attributed to several key functions, including as a proinflammatory cytokine, as an inducer of metalloproteinases and as an activator and recruiter of immune cells including macrophages (34, 35).

Fig. 5. Reconstitution of rMIF into WT and MIF−/− mice exacerbates RRV disease. The 20-d-old (A) MIF−/− or (B) C57BL/6 WT mice were infected with 10⁴ pfu RRV alone, 50 ng recombinant mouse MIF alone, or 10⁶ pfu of RRV plus 50 ng MIF. All injections were by the subcutaneous route into the right thorax. Mice were reinjected with 50 ng MIF every 48 h, as indicated by arrows. Mice were scored for the development of hindlimb dysfunction. Group infected with MIF alone showed no disease signs for the duration of the experiment. Each datapoint represents the mean ± SEM of up to five mice and is representative of two independent experiments. *P < 0.05 using a Mann-Whitney test; note, statistical differences were unable to be determined after 15 d.p.i. of 10⁶ pfu RRV because of the loss of too many mice, reducing the RRV+MIF-infected mice sample size to two.

Fig. 6. Treatment with ISO-1 MIF antagonist ameliorates RRV-arthritic disease. The 20-d-old C57BL/6 WT mice were infected subcutaneously with 10⁴ pfu RRV or mock-infected with diluted alone. At the onset of disease and at 24-h intervals thereafter, mice were treated with 50 μL of either the MIF ISO-1 antagonist (1 mg/mL) or ISO-1 diluent intraperitoneally. Mice were weighed and scored for disease symptoms every 24 h, as outlined above. Each datapoint represents the mean ± SEM of up to five mice and is representative of at least two independent experiments. *P < 0.05 using a Mann-Whitney test.
Given the role of the innate immune system in viral infections, the central role of macrophages in the pathogenesis of alphavirus infection and the similarities between RA and alphavirus-induced arthritis, we set out to speculate on the role for MIF in modulation of alphavirus disease. MIF’s involvement in RA was first identified using a murine collagen-induced arthritis model in 1997 (36) and then in a more severe rat adjuvant-induced arthritis model in 1999 (37). In the latter study, MIF expression was increased in the synovial tissues and serum of rats with arthritis. Similarly, in the murine RRV disease model, serum MIF concentration was increased in WT mice following RRV infection. The increase in serum MIF coincided with the onset of clinically evident disease, suggesting that the actions of MIF exacerbate the disease but do not contribute to the establishment of infection. MIF concentration was also found to be up-regulated in the tissues of the ankle joint at day 5 and 10 p.i. and the quadriceps muscles at day 10 p.i. As both these tissues are primary sites of RRV infection, the results suggest that there may be an association between the presence of RRV and the expression of MIF.

The impact of MIF on alphavirus disease was assessed using RRV infection of MIF−/− mice, in which arthritic features were found to be almost entirely abrogated compared with WT mice. Histological analysis revealed mild inflammation and corresponding mild muscle-tissue damage in the RRV-infected MIF−/− mice, in contrast to the more severe inflammation and damage seen in RRV-infected WT mice. Despite a reduction in disease severity, peak viral titers were unaffected, suggesting that any immunocompromise associated with MIF deficiency did not result in clearance of the virus. In consideration of anti-MIF therapy in viral disease, MIF−/− mice have been used in similar studies of RA, showing a reduction of arthritis in MIF-deficient mice, which was found to correspond to reduced histological arthritis and cartilage damage (27). Given that viral replication and load in the RRV-infected MIF−/− mice was comparable to WT mice, we interpret the reduction in disease severity in MIF−/− mice as an immunopathological effect of the MIF deficiency.

MIF is known to act as a proinflammatory cytokine, stimulating the expression of TNF, IL-6, IL-1, and IL-8 (24). In this study, IFN-γ and MCP-1 were up-regulated in the ankle joint and quadriceps muscle of RRV-infected WT mice, compared with mock-infected mice, as has been previously reported (18, 21). The down-regulation of MCP-1 expression in the absence of MIF is of particular interest. MCP-1 is a potent monocyte chemoattractant (38) and has been previously shown to play an important role in RRV disease, with the inhibition of MCPs by the indazole derivative drug Bindarit, resulting in a significant decrease in the severity of RRV-induced disease (21). MIF has been shown to regulate MCP-1 expression in its promotion of macrophage recruitment in vivo (22) and leukocyte endothelial interactions in vitro (39). In the present study, the increase in MCP-1 expression and concentration seen at peak RRV-disease in WT mice was significantly diminished in MIF−/− mice, a result that was also seen during the earlier stages of infection. These results suggest that an important aspect of the MIF-induced response to RRV infection is the induction of MCP-1 expression, thereby contributing to the marked macrophage infiltration observed in RRV-infected mice.

In addition, at peak disease, MIF−/− mice showed a significant decrease in the expression of IFN-γ in the ankle joint, with a corresponding decrease in the quadriceps muscle. In support of previous studies, which have shown that the functions of MIF and IFN-γ are closely linked (32, 40, 41), the present data suggest a role for MIF in the regulation of IFN-γ within joints during RRV infection. However, the absence of MIF did not cause a uniform reduction of cytokine expression. There were no significant differences seen in the expression of TNF-α between MIF−/− and WT mice following RRV-infection. Overall, the results suggest that the reduction of disease severity observed in MIF-deficient mice may be explained by reductions in MCP-1 and IFN-γ expression in these mice, with MCP-1 being particularly relevant because of its role in monocyte/macrophage recruitment, a key process known to be involved in RRV pathogenesis.

Several studies have investigated the role of MIF in viral infection; however, this remains an area of limited knowledge. A number of in vitro studies on the role of MIF in viral infections, including influenza, human cytomegalovirus, and Sindbis virus (22–44), have shown an increase in the levels of MIF following infection. These findings, however, are limited because of the absence of corresponding in vivo studies. On the other hand, WNV and Japanese encephalitis virus, both arboviruses from the Flaviviridae family, have been shown to cause a significant increase in MIF mRNA in mouse brains (30, 45), and in the case of the WNV study, in vivo antagonism of MIF by genetic deletion, antibody, and antagonist treatment all resulted in decreased viral neuroinvasion. Moreover, Dengue virus, another flavivirus, was shown to up-regulate MIF in response to viral infection, with MIF-deficient mice showing increased survival compared with WT mice (46). Although these studies show a role for MIF in response to flavivirus infection and outcome, they are limited in their ability to demonstrate a role for MIF in the development of clinical signs and disease. Taken together, these studies suggest a previously unappreciated role for MIF in viral infection.

Currently, the only treatment available for alphavirus-induced disease is the use of broad range anti-inflammatory drugs, with no specific prophylactics available. Similarly, anti-inflammatory drugs, such as glucocorticoids (GCs), are currently the main treatment used for other inflammatory diseases, including RA. Interestingly, although GCs act to reduce inflammation, studies have found that expression of MIF can actually be induced by GCs, suggesting that MIF can act as a physiological antagonist to the anti-inflammatory effects of GCs (28, 47, 48). There have been a number of studies focused on the potential of MIF antagonists in the treatment of inflammatory diseases (reviewed in ref. 47), with the particular aim of developing MIF-antagonists as a form of “steroid-sparing” treatment. Whereas the focus remains on immunoinflammatory diseases, such as RA, systemic lupus erythematosus, and atherosclerosis, this study illustrates that an application of anti-MIF pharmaceuticals to inflammatory infectious diseases, such as alphavirus arthritis, remains promising.

Materials and Methods

Virus and Cells. Stocks of the WT T48 strain of RRV were generated from the full-length T48 cDNA clone (kindly provided by Richard Kuhn, Purdue University, West Lafayette, IN) (49). Transcripts were electroporated into vero cells (ATCC; CCL-81) and supernatants collected 24 h p.i. All titrations were performed by plaque assay on vero cells as described previously (17).

Mice. C57BL/6 WT mice were obtained from the Animal Resource Centre (Perth, Australia) and MIF-deficient mice (MIF−/−) (on the C57BL/6 background) (50) were obtained from Monash Medical Centre (Melbourne, Australia) and bred in-house. All animal experiments were performed in accordance with the guidelines set out by the University of Canberra Committee for Ethics in Animal Experimentation. The 20-d-old C57BL/6 male and female mice, of equal distribution, were inoculated subcutaneously in the thorax below the right forelimb with 104 pfu virus, diluted in PBS to a final volume of 50 μL. Mock-infected mice were inoculated with PBS diluent alone. Mice were weighed and scored for disease signs every 24 h. Disease scores were assessed based on animal strength and hind-leg paralysis, as outlined previously (20), using the following scale: 0, no disease signs; 1, ruffled fur; 2, very mild hindlimb weakness; 3, mild hindlimb weakness; 4, moderate hindlimb weakness and dragging of hindlimbs; 5, severe hindlimb weakness/dragging; 6, complete loss of hindlimb function; 7, moribund; and 8, death.

For treatment with rMIF (R & D Systems; reconstituted with 0.2% BSA in PBS), 20-d-old MIF−/− or C57BL/6 WT mice were either infected with 106 pfu RRV alone, diluent alone, treated with 50 ng rMIF alone, or infected with 106 pfu RRV and treated with 50 ng rMIF. Infected and uninfected mice treated with rMIF were reinfected with 50 ng of rMIF every 48 h up to day 14 p.i. All injections were subcutaneous in the thorax in a 50-μL volume, using 0.2% BSA in PBS as the diluents. For treatment with MIF ISO-1 antagonist (Merc; reconstituted with 10% DMSO in PBS to a final concentration of 1 mg/mL), 20-d-old C57BL/6 WT mice were either infected with 106 pfu RRV or mock-infected with PBS. At the first signs of disease (ruffled fur and lethargy), mice were treated with 50 μL of either the MIF ISO-1 antagonist or the 10% DMSO in PBS diluent via the intraperitoneal route, every 24 h up to day 14.
14 p.i. In all experiments, mice were weighed and scored for disease signs every 24 h, as outlined above. For histology, mice were killed and perfused with 4% paraformaldehyde (PFA). Tissues were collected, fixed in 4% PFA, ankles decalcified, followed by paraffin-embedding. Five-micrometer sections were prepared and stained with H&E (Histology facility, Australian National University, Canberra, Australia). For EBD methods, see SI Materials and Methods.

For IHC, 5-μm paraffin-embedded sections were dewaxed, rehydrated, then incubated with rabbit serum for 20 min. Sections were incubated with primary goat anti-human MIF monoclonal (R & D Systems) or mouse anti-control IgG overnight at 4°C. Endogenous peroxidase was blocked with 0.75% hydrogen peroxide in methanol and sections then stained with rabbit anti-goat IgG horseradish peroxidase (R & D Systems) for 30 min. Color was developed with 3, 3'-diaminobenzidine black (DAB; Vector Laboratories) enzyme substrate according to the manufacturer's instructions and counter-stained with fast red.

Real-Time PCR. For real-time PCR, see SI Materials and Methods.

For statistical analysis, the statistical test chosen was dependent on the results of normality analyses. The normal distribution of data was examined using the D'Agostino–Pearson normality test before analysis with these parametric tests. Clinical scores were analyzed using the nonparametric Mann–Whitney test. Statistics were performed with GraphPad Prism 5.02.


Supporting Information

**Herrero et al. 10.1073/pnas.1101089108**

**SI Materials and Methods**

**Evan’s Blue Dye.** To detect myofiber damage, mice were injected intraperitoneally with 1% Evan’s blue dye (EBD) 6 h before being killed. Quadriceps were collected, embedded in OCT (Tissue-Tek), then frozen in an isopentane histobath. Next, 10-μm cryosections were fixed with acetone on gelatin-coated slides, then stained with DAPI (Molecular Probes, Invitrogen) and mounted with Vectashield (Vector Laboratories) for analysis by fluorescence microscopy. EBD+ cells showed a bright red emission.

**Real-Time PCR.** Total RNA was isolated with TriReagent (Ambion) according to the manufacturer’s instructions. RNA was reverse-transcribed with random primers (Promega) and cDNA generated with Mouse Murine Leukemia Virus Reverse Transcriptase (Invitrogen). A total of 1 μg of cDNA was used for quantitative real-time PCR (Biorad) using commercially available QuantiTec primers for monocyte chemotatic protein-1 (MCP-1), TNF-α, IFN-γ, and macrophage migration inhibitory factor (MIF) (Qiagen) with FastStart SYBR-Green Master (Roche).

**ELISA.** MIF levels in the serum, quadriceps muscle, and ankle joint tissues were determined using a commercially available murine MIF ELISA kit from USCN Life according to the manufacturer’s instructions. The concentrations of MCP-1, TNF-α, and IFN-γ in quadriceps and ankle tissues were determined by ELISA using commercially available kits from BD Biosciences, according to the manufacturer’s instructions. Tissues were homogenized in PBS using a TissueLyser (Qiagen) before assay and cytokine levels were expressed as petagram per milligram of total protein, as determined by Micro BCA Protein Assay (Pierce, Thermo Fisher). The sensitivity of each assay was as follows: 332 pg/mL (MIF), 14 pg/mL (MCP-1), 30 pg/mL (TNF-α), and 18 pg/mL (IFN-γ).

![Graphs A, B, and C](https://via.placeholder.com/150)

**Fig. S1.** MIF deficiency results in small decrease in Ross River virus (RRV) titers in the ankle but not in the serum and quadriceps muscle. The 20-d-old C57BL/6 WT or MIF−/− mice were infected subcutaneously with 10⁴ pfu RRV. At days 1, 3, 5, and 10 p.i. the (A) serum, (B) quadriceps, and (C) ankle tissues were harvested, homogenized, and the amount of infectious virus determined by plaque assay on Vero cells. Each datapoint represents the mean ± SEM of four to six mice. *P < 0.05 using two-way ANOVA with Bonferroni posttest.
RRV-induced tissue damage is reduced in MIF−/− mice. The 20-d-old C57BL/6 WT and MIF−/− mice were infected subcutaneously with 10⁴ pfu RRV or mock-infected with diluent alone. At 10 d p.i., mice were injected intraperitoneally with 1% EBD and 6 h later, mice were killed, quadriceps muscle tissue removed, and 10-μm cryosections generated. The uptake of EBD (red) and DAPI (blue) was visualized by fluorescence microscopy. (A) mock-infected WT, (B) mock-infected MIF−/−, (C) RRV-infected WT, (D) RRV-infected MIF−/−. Images are representative of at least three to five mice per group (magnification, 200×).
MIF contributes to RRV-induced cytokine expression at the site of inflammation. The 20-d old C57BL/6 WT (gray bars) and MIF−/− (white bars) mice were infected subcutaneously with 10^4 pfu RRV or mock-infected with diluent alone. (A) Total RNA from quadriceps muscle and ankle joint tissues was isolated at day 10 p.i. and analyzed for mRNA expression by qRT-PCR. Data were normalized to the housekeeping gene HPRT1 and expressed as relative expression. *P < 0.05 using one-way ANOVA with Tukey's posttest. (B) Quadriceps muscle and ankle joint tissues were isolated at day 10 p.i. and homogenized in PBS, with cytokine protein level determined by ELISA. *P < 0.05 using a Student t test. Each bar represents the mean ± the SEM for three to five mice per group.
Fig. S4. MIF affects RRV-induced cytokine expression at the early stages of infection. The 20-d-old C57BL/6 WT (gray bars), MIF−/− (white bars) mice were infected subcutaneously with 10⁴ pfu RRV or mock-infected with diluent alone. Quadriceps muscle and ankle joint tissues were isolated at days 1, 3, and 5 p.i., homogenized in PBS, and cytokine protein level determined by ELISA. Each bar represents the mean ± the SEM for three to five mice per group. *P < 0.05 using two-way ANOVA with Bonferroni posttest.

Fig. S5. Reconstitution of recombinant MIF (rMIF) into WT and MIF−/− mice exacerbates RRV-induced weight loss. The 20-d-old (A) MIF−/− or (B) C57BL/6 WT mice were infected subcutaneously with 10⁴ pfu RRV alone, with diluent alone, 50 ng recombinant mouse MIF alone, or 10⁴ pfu of RRV plus 50 ng MIF. Mice receiving MIF treatment were reinjected with 50 ng MIF every 48 h. Mouse weight was monitored at 24-h intervals. Each datapoint represents the mean ± SEM of at least five mice and is representative of two independent experiments. *P < 0.05 RRV+ MIF infection compared with RRV-alone infected mice using two-way ANOVA with Bonferroni posttest. Additionally, RRV infection significantly reduced weight gain compared with the corresponding MIF-alone infection or the diluent-alone infection, with P < 0.05 for all time points after day 2 (both RRV alone and RRV + MIF) (A) and P < 0.05 for all time points after day 1 (RRV alone) or day 2 (RRV + MIF) (B).
Treatment with ISO-1 MIF antagonist reduces RRV-induced weight loss. The 20-d-old C57BL/6 WT mice were infected subcutaneously with $10^4$ pfu RRV or mock-infected with diluent alone. At onset of disease and at 24-h intervals thereafter, mice were treated with 50 $\mu$L of either the MIF ISO-1 antagonist (1 mg/mL) or ISO-1 diluent intraperitoneally. Mouse weight was monitored at 24-h intervals. Each datapoint represents the mean ± SEM of at least five mice and is representative of two independent experiments. *$P < 0.05$ RRV-infected MIF ISO-1 treated compared with RRV-infected untreated using two-way ANOVA with Bonferroni posttest.